Drug Trial Radar · NCT04544449
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
985
Actual
Start
Oct 26, 2020
Primary completion
Sep 17, 2025
Study completion Jul 21, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.
Conditions
- Multiple Sclerosis, Primary Progressive
Interventions
FenebrutinibDrug
Participants will receive fenebrutinib.
OcrelizumabDrug
Participants will receive ocrelizumab.
Placebo matched to ocrelizumabDrug
Participants will receive ocrelizumab-matching placebo.
Placebo matched to fenebrutinibDrug
Participants will receive fenebrutinib-matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Onset of Composite 12-Week Confirmed Disability Progression (cCDP12)Time frame: Minimum of 120 weeks
Locations
190 sites in 28 countries. Site status is shown where the registry gives one.
Alabama Neurology Associates
Homewood, Alabama
Sutter East Bay Medical Foundation
Berkeley, California
Fullerton Neurology and Headache Center
Fullerton, California
Palo Alto Medical Foundation Research Center
Sunnyvale, California
University of Colorado Denver
Aurora, Colorado
Yale University School Of Medicine
Fairfield, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
Neurology Associates PA
Maitland, Florida
Neurological Services of Orlando
Orlando, Florida
University of South Florida
Tampa, Florida
Josephson Wallack Munshower Neurology PC
Indianapolis, Indiana
University of Kansas Medical Center
Kansas City, Kansas
Johns Hopkins University School Of Medicine
Baltimore, Maryland
Dragonfly Research, LLC
Wellesley, Massachusetts
Wayne State University
Detroit, Michigan
Minneapolis Clinic of Neurology
Golden Valley, Minnesota
Washington University
St Louis, Missouri
Cleveland Clinic Lou Ruvo
Las Vegas, Nevada
Hackensack U Med Ctr
Hackensack, New Jersey
Barnabas Health Ambulatory Care Center
Livingston, New Jersey
Jersey Shore University Medical Centre
Neptune City, New Jersey
Rutgers New Jersey Medical School
Newark, New Jersey
Holy Name Hospital
Teaneck, New Jersey
Dent Neurological Institute
Amherst, New York
Columbia University Medical Center
New York, New York
University of Rochester
Rochester, New York
Stony Brook University Medical Center
Stony Brook, New York
SUNY Upstate Medical University
Syracuse, New York
Atrium Health Neurosciences Institute ? Charlotte
Charlotte, North Carolina
Raleigh Neurology Associates
Raleigh, North Carolina
Miami Valley Hospital South
Centerville, Ohio
UC Health, LLC.
Cincinnati, Ohio
OhioHealth Riverside Methodist Hospital
Columbus, Ohio
Providence Brain and Spine Institute
Portland, Oregon
Neurology Clinic PC
Cordova, Tennessee
Hope Neurology
Knoxville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Uni of Texas Health Science Center At Houston
Houston, Texas
Texas Institute for Neurological Disorders
Sherman, Texas
Evergreen MS Center
Kirkland, Washington
Showing 40 of 190 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.